Mantle Cell Lymphoma News

News

MRD Linked to Worse Survival Outcomes in Patients With MCL

01/13/2021

Journal of Clinical Pathways

News

Treatment Patterns and Outcomes Among US Patients With MCL Treated With Ibrutinib

11/24/2020

Journal of Clinical Pathways

News

Significant Economic and Health-Related QoL Burden Associated With MCL

10/09/2020

Journal of Clinical Pathways

News

Novel Health Utility Measure Promising for Cost-Effectiveness Analysis of Cancer Treatments

07/22/2020

FACT-8D, a novel cancer-specific, preference-based measure of health, derived from the Functional Assessment of Cancer Therapy – General (FACT-G) questionnaire, may offer an alternative method to generate utilities...

...

07/22/2020

Journal of Clinical Pathways

News

Optimal Real-World Immunochemotherapy Regimen for Patients With MCL

06/25/2020

A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...

A...

06/25/2020

Journal of Clinical Pathways

News

Predicting Clinical Outcomes of Patients With High-Risk MCL

06/18/2020

Patients with high-risk mantle cell lymphoma (MCL) biology—defined by blastoid variance, Ki-67 greater than 30%, or high p53 immunohistochemistry expression—are more likely to experience shorter failure-free and...

...

06/18/2020

Journal of Clinical Pathways

News

Modified MIPI Scoring System Provides Clinical, Biological Prognostic Indicators for MCL

06/11/2020

At the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020), researchers from the North American Mantle Cell Lymphoma (MCL) Consortium offered clinical, biological, and genomic markers that...

At the...

06/11/2020

Journal of Clinical Pathways

News

Effective, Less Toxic Treatment Option Identified for Aggressive B-Cell Lymphoma

05/29/2020

Risk-adapted dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) therapy is effective and well tolerated in adults with Burkitt lymphoma regardless of age or...

...

05/29/2020

Journal of Clinical Pathways

News

Practice Patterns, Predictors of Survival for Older Patients With MCL

05/27/2020

A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...

A new...

05/27/2020

Journal of Clinical Pathways

News

Real-World HRU, Costs in Patients With MCL Treated With Drug Combo vs Chemoimmunotherapy

05/20/2020

Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...

...

05/20/2020

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Mantle Cell Lymphoma News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products